As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a Arbutus Biopharma Corporation forecast:
10 Analysts have issued a Arbutus Biopharma Corporation forecast:
Mar '25 |
+/-
%
|
||
Revenue | 6.40 6.40 |
51%
51%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -65 -65 |
17%
17%
|
EBIT (Operating Income) EBIT | -67 -67 |
17%
17%
|
Net Profit | -77 -77 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
Head office | Canada |
CEO | Lindsay Androski |
Employees | 44 |
Founded | 2005 |
Website | www.arbutusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.